Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05373745
Collaborator
(none)
260
1
2
54.4
4.8

Study Details

Study Description

Brief Summary

The investigators aim to conduct a fully powered randomized controlled trial to compare the efficacy of two symptom management programs for older adults with early cognitive decline (either self-reported or confirmed by testing) and chronic pain, Active Brains 1 and Active Brains 2. The investigators will assess how each program may help in improving multimodal physical, cognitive and emotional function. The investigators will also assess whether improvements in outcomes from the two programs are maintained through 6-months follow-up. The investigators will also explore whether improvements in outcomes are mediated by nonadaptive pain reactions, adaptive coping, social factors and compensatory strategies and modified by demographic and clinical predictors. Both programs will be delivered virtually (Zoom).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Active Brains 1
  • Behavioral: Active Brains 2
N/A

Detailed Description

The investigators aim to conduct a fully powered randomized controlled trial to establish efficacy of two symptom management programs for older adults with early cognitive decline (either self-reported or confirmed by testing) and chronic pain, Active Brains 1 and Active Brains 2. The investigators will assess how the two programs may help in improving multimodal physical, cognitive and emotional function. The investigators will also assess whether improvements in outcomes are maintained through 6-months follow-up. The investigators will also explore whether improvements in outcomes are mediated by nonadaptive pain reactions, adaptive coping, social factors and compensatory strategies and modified by demographic and clinical predictors, and type of early cognitive decline. Both programs will be delivered virtually (Zoom).

Each group meets for eight, 90 minutes sessions over the secure Zoom platform. Each group has 5-8 participants. Participants receive a treatment manual. There are 3 assessment points: baseline, post program and 6-month follow-up. Assessments involve self-report questionnaires, a walk test and a neuropsychological evaluation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
260 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Addressing the Chronic Pain-Early Cognitive Decline Comorbidity Among Older Adults; The Active Brains Study
Actual Study Start Date :
Jun 20, 2022
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Brains 1

Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Behavioral: Active Brains 1
Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Placebo Comparator: Active Brains 2

This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., "Sleep", "Nutrition", "Healthy Weight" and "Medical appointments". The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Behavioral: Active Brains 2
This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., "Sleep", "Nutrition", "Healthy Weight" and "Medical appointments". The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Outcome Measures

Primary Outcome Measures

  1. Change in PROMIS Physical Function [0 Weeks, 8 Weeks, 6 Months]

    Change in rate of a participant's capability rather than performance of physical activities, with items ranging from 1-4, and total scores ranging from 8-40, with a higher score reflecting greater physical function

  2. Change in PROMIS Pain Interference - Short Form 6b V1.0 [0 Weeks, 8 Weeks, 6 Months]

    Change in the self-reported consequences of pain on relevant aspects of a person's life.

  3. Change in Step Count via the ActiGraph GT3XP-BTLE Accelerometer [0 Weeks, 8 Weeks, 6 Months]

    Measures the change in activity during the 7 days preceding baseline assessment, throughout the intervention period, and 7 days preceding 6-month follow-up. Assess number of steps, as well as minutes of activity (light, moderate, vigorous and minutes of sedentary time).

  4. Change in six-minute walk test (6MWT) [0 Weeks, 8 Weeks, 6 Months]

    Assesses changes distance walked in 6 minutes.

Secondary Outcome Measures

  1. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [0 Weeks, 8 Weeks, 6 Months]

    A comprehensive assessment that includes measures of memory, executive functioning, cognitive flexibility, attention, (etc.) and provides a measure of global cognition.

  2. Montreal Cognitive Assessment (MoCA; audiovisual version) [0 Weeks, 8 Weeks, 6 Months]

    Assesses several cognitive domains and detection of mild cognitive impairment (MCI), with scores ranging from 0-30 and lower scores indicating greater cognitive decline.

  3. Everyday Cognition Scale (eCog-12) [0 Weeks, 8 Weeks, 6 Months]

    Rate of participant's cognitively mediated functional abilities, with items ranging from 1-5, with a total score ranging from 12-60, with higher scores indicating greater cognitive decline.

  4. PROMIS Depression [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's negative mood, social cognition and views of self, with items ranging from 1-5, total scores ranging from 8-40, and a higher score reflecting higher levels of depression.

  5. PROMIS Anxiety [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's fear, anxious, hyper arousal and somatic symptoms pertaining to arousal, with items ranging from 1-5, total scores ranging from 8-40, and a high score reflecting higher levels of anxiety.

  6. Numerical Rating Scale [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's pain at rest and with activity using a Likert scale with 0 being no pain and 10 being worst possible pain.

  7. Pain Catastrophizing Scale [0 Weeks, 8 Weeks, 6 Months]

    10. Pain Catastrophizing Scale

  8. Tampa Kinesiophobia Scale [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's fear of movement, with items ranging from 1-4, and total scores ranging from 17 to 68, and higher scores indicating higher levels of fear of movement

  9. Pain Self-Efficacy [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's confidence to do various activities despite their pain, with items ranging from 0-6, and a higher score showing greater levels of confidence with pain self-efficacy, with total scores ranging from 0-60

  10. Self-Compassion Scale [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's amount of self-compassion, with items ranging from 1-5, and total scores ranging from 12-60 and higher scores indicating higher levels of self-compassion

  11. Measure of Current Status [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's self-reported perceived stress self-management skills, with items ranging from 0-4 and a total score ranging from 0-52, and higher scores reflecting more usage of stress self-management skills

  12. Gratitude Questionnaire [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's proneness to experience gratitude in daily life, with items ranging from 1-7, total scores ranging from 6-24, and a higher score indicating greater amount of gratitude

  13. Toronto Mindfulness Scale [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's state mindfulness in the moment, with items ranging from 1-5, total scores ranging from 13-65, and a higher score indicating a greater amount of state-level mindfulness.

  14. PROMIS Loneliness [0 Weeks, 8 Weeks, 6 Months]

    Measure of an individual's perceptions that one is alone, lonely, or socially isolated from others, with items ranging from 1-5, total scores ranging from 4-20, and a higher score indicating a greater degree of loneliness.

  15. PROMIS Satisfaction with Social Roles and Activities [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's perceived satisfaction with social functioning, with items ranging from 1-5, total scores ranging from 8-40, and a higher score indicating higher satisfaction with social functioning

  16. Memory Compensation Questionnaire [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's use of cognitive compensatory strategies for actual or perceived memory loss, items range from 0-4, total scores range from 0-52 with a higher score reflecting greater use of compensatory strategies.

  17. The Pain, Enjoyment of Life and General Activity (PEG) Scale [1 Week, 2 Weeks, 3 Weeks, 4 Weeks, 5 Weeks, 6 Weeks, 7 Weeks]

    Rate of a participant's chronic pain level, measured by pain intensity and pain interference. Items range from 0-10, and total scores range from 0-30, with higher scores indicating greater levels of chronic pain.

  18. Global Cognitive and Social Engagement [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's perceived engagement in mentally stimulating social and cognitive activities, with items ranging from 0-4, total scores ranging from 0 to 20, and higher scores indicating higher perceived activity engagement.

  19. Quota-Based Pacing [0 Weeks, 8 Weeks, 6 Months]

    Rate of a participant's perceived use of quota-based activity pacing. Items range from 0-4, and total scores range from 0-16, with higher scores indicating greater use of quota-based pacing.

  20. Pain Interference Weekly Measure [1 Week, 2 Weeks, 3 Weeks, 4 Weeks, 5 Weeks, 6 Weeks, 7 Weeks]

    Brief measure assessing the degree to which pain interferes with a participant's ability to meet their step count goal and degree to which it contributes to memory-related problems. Only administered to the Active Brains 1 group.

Other Outcome Measures

  1. Demographics [0 Weeks]

    Questionnaire that asks individuals to report on: date of birth, gender, weight, height, handedness, ethnicity, race, martial status, education level, employment status, type of job, income, pain diagnoses, length of chronic pain, other medical conditions, mental health conditions, pain medications, cognitive preservations

  2. Treatments [0 Weeks]

    Questionnaire that asks individuals to report on: use of prescription pain medication, use of supplemental memory medication, and engagement in physiotherapy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and female outpatients, age 60 years or older

  • Have nonmalignant chronic pain for more than 3 months

  • Reports early cognitive decline (subjective or objective)

  • Telephone Interview for Cognitive Status-30 score greater than or equal to 17

  • Functional Activities Questionnaire score less than 9

  • Able to perform a 6-minute walk test at an accelerated pace

  • English fluency/literacy

  • Willingness and ability to participate and use an ActiGraph watch and smartphone app to view and sync the step count and sleep data

  • Free of concurrent psychotropic or pain medication for at least 2 weeks prior to initiation of treatment, OR stable on current psychotropic or pain medication for a minimum of 6 weeks and willing to maintain a stable dose

  • Cleared by a medical doctor for study participation and no self-reported concerns about physical functioning on the revised Physical Activity Readiness Questionnaire (PAR-Q; score 0)

Exclusion Criteria:
  • Diagnosed with dementia or neurodegenerative disease

  • Diagnosed with medical illness expected to worsen in the next 6 months

  • Diagnosed with serious untreated mental illness (i.e., schizophrenia) or untreated substance use disorder

  • Current suicidal ideation reported on self-report

  • Engaging in regular mindfulness practice > 45 min/week or has completed a course of cognitive behavioral therapy in the past 3 months

  • Regular use of a digital-monitoring device

  • Engagement in regular intensive physical exercise for >30 minute daily

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

  • Principal Investigator: Ana-Maria Vranceanu, PhD, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ana-Maria Vranceanu, PhD, Associate Professor/Director, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05373745
Other Study ID Numbers:
  • 2021P00281
First Posted:
May 13, 2022
Last Update Posted:
Jun 30, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ana-Maria Vranceanu, PhD, Associate Professor/Director, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 30, 2022